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ABSTRACT: Extracellular vesicles (EVs), such as exosomes,
can mediate long-distance communication between cells by
delivering biomolecular cargo. It is speculated that EVs undergo
back-fusion at multivesicular bodies (MVBs) in recipient cells
to release their functional cargo. However, direct evidence is
lacking. Tracing the cellular uptake of EVs with high resolution
as well as acquiring direct evidence for the release of EV cargo
is challenging mainly because of technical limitations. Here, we
developed an analytical methodology, combining state-of-the-
art molecular tools and correlative light and electron
microscopy, to identify the intracellular site for EV cargo
release. GFP was loaded inside EVs through the expression of
GFP-CD63, a fusion of GFP to the cytosolic tail of CD63, in EV producer cells. In addition, we genetically engineered a cell
line which expresses anti-GFP fluobody that specifically recognizes the EV cargo (GFP). Incubation of anti-GFP fluobody-
expressing cells with GFP-CD63 EVs resulted in the formation of fluobody punctae, designating cytosolic exposure of GFP.
Endosomal damage was not observed in EV acceptor cells. Ultrastructural analysis of the underlying structures at GFP/
fluobody double-positive punctae demonstrated that EV cargo release occurs from endosomes/lysosomes. Finally, we show
that neutralization of endosomal pH and cholesterol accumulation in endosomes leads to blockage of EV cargo exposure. In
conclusion, we report that a fraction of internalized EVs fuse with the limiting membrane of endosomes/lysosomes in an
acidification-dependent manner, which results in EV cargo exposure to the cell cytosol.
KEYWORDS: extracellular vesicles, endosomes, nanobody, endosomal escape, cargo delivery, correlative microscopy
Secreted factors, including messenger molecules andextracellular vesicles, allow long-distance communicationbetween mammalian cells. Extracellular vesicles (EVs),
including exosomes, microvesicles, and apoptotic bodies, carry
biomolecules (lipids, proteins, nucleic acids) and impart
phenotypic changes in recipient cells. EVs have been reported
to play a role in a wide variety of processes within the human
body, including immune response, neurodegenerative disease
pathogenesis, viral dissemination, and tumor formation and
metastasis.1−8 Next to their role in cell−cell communication,
EVs show promise as biological drug delivery vehicles.9−11
Multiple types of EVs exist, which are first categorized on the
basis of their biogenesis: (i) Microvesicles and (ii) apoptotic
bodies are generated by plasma membrane outward budding,
whereas (iii) exosomes are created by endosome membrane
invagination, resulting in intraluminal vesicles within multi-
vesicular bodies (MVBs). Subsequent fusion of MVBs with the
plasma membrane results in exosome release from cells. EVs
can enter cells in the local or distant environment,1,12−18 via
fusion and/or endocytosis.19−24
Different mechanisms for EV cargo release in recipient cells
have been proposed, including (i) fusion with the plasma
membrane,19,20 (ii) kiss and run fusion with the endoplasmic
reticulum,21 (iii) fusion with the endosome membrane,22 and
(iv) endosomal rupture (Figure 1).22,25,26 Although fusion of
EVs with the plasma membrane of recipient cells has been
proposed as a mechanism for content release,19,20 endocytosis
is the major pathway of EV uptake.21−24 Escape of the EV
content from the endosomal confinement is then a require-
ment for its functionality, as it needs to access cytoplasmic
targets in the host cell, such as the RNA-induced silencing
complex (RISC) machinery for miRNAs. Possible mechanisms
for cargo release of EVs from endosomes include endosomal
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lysis, endosomal permeabilization, and membrane fusion
between EV and endosomal membrane.27
The incidence of cytosolic delivery of EV cargo has been
largely indirectly inferred from functional studies in which, for
example, EV-mediated delivery of miRNA was shown to result
in altered gene expression.15,28−32 However, direct evidence for
EV content release into the cytosol of recipient cells is lacking.
Here, we employed state-of-the-art molecular tools with
correlative light and electron microscopy (CLEM)33 to detect
endosomal lysis and identify the underlying ultrastructure of
intracellular sites of EV cargo exposure to the cell cytosol,
following EV uptake in HEK293T cells. To this end,
fluorescent GFP-CD63 EVs were generated, carrying GFP at
the interior EV membrane. Cytosolic expression of anti-GFP
fluobody,34 an mCherry-tagged anti-GFP single-domain anti-
body (nanobody),35,36 in recipient cells was exploited to detect
EV cargo exposure to the cytosol (Figure 1).
RESULTS AND DISCUSSION
Extracellular Vesicles Are Internalized via Endocyto-
sis. In order to study the processing of exogenously added EVs
in mammalian cells by fluorescence light microscopy (LM), a
stable GFP-CD63 HEK293T cell line was generated for the
production of fluorescently labeled EVs. In GFP-CD63
HEK293T cells, GFP fluorescence showed cell surface staining
and a punctate staining pattern consistent with the cytoplasmic
distribution of endosomes (Figure S1A), which corresponds
with the localization of endogenous CD63.37 EVs were isolated
by differential centrifugation of the conditioned cell culture
medium, with final ultracentrifugation at 100,000×g (small
EVs). Following isolation, both wild-type (WT) and GFP-
CD63 EVs showed cup-shaped vesicular morphology and a
diameter of 100−150 nm, by electron microscopic inves-
tigation (Figure S1B). WT and GFP-CD63 EVs displayed a
similar extent of enrichment of EV marker proteins and low
levels of the Golgi protein golgin-97, an EV negative marker, in
comparison to the respective parent producer cells (Figure
S1C). Furthermore, size distribution analysis using dynamic
light scattering confirmed the similar size of WT and GFP-
CD63 EVs and also their surface charge (ζ-potential) was
shown to be identical (Figure S1D−F). Hence, GFP-CD63
expression did not alter morphology nor size or surface charge
of the EVs. Therefore, GFP-CD63 EVs were considered similar
to WT EVs and were further used in the study.
Upon incubation of WT HEK293T cells with GFP-CD63
EVs, a punctate staining pattern was observed throughout the
cytosol by LM, suggesting the involvement of endocytosis in
EV uptake by cells (Figure 2A). Indeed, inhibition of
endocytosis through the use of the dynamin inhibitor
dynasore38 resulted in a decrease in EV uptake (Figure
S2A). In addition, EV uptake was inhibited at a nonpermissive
temperature (4 °C) for endocytosis (Figure S2B). Taking a
CLEM approach allowed for the identification of the
ultrastructure of the GFP-positive spots by EM (Figure
2B,C), revealing the presence of GFP-CD63 EVs in
membranous compartments, that is, endosomes (Figure 2C
and Figure S3). To confirm the presence of GFP-CD63 EVs
within these endosomal structures, GFP was immunolabeled
and detected with a secondary antibody conjugated to QD655.
Indeed, the endosomes that were identified by EM (Figure
2C) and appeared positive for GFP by LM examination
(Figure 2B) were also found positive for GFP after
immunolabeling (Figure 2D). Taken together, the findings
demonstrate that GFP-CD63 EVs are taken up by HEK293T
cells via endocytosis. Of note, not all compartments that were
positive for GFP in the CLEM image stained positive for GFP
upon immunolabeling. This can be explained by the low
efficiency of EM immunolabeling in general.39
Extracellular Vesicles Do Not Induce Endosomal
Permeabilization. Following endocytosis of EVs by
HEK293T cells, a prerequisite for delivery of their cargo to
the cell cytosol is their escape from endosomal confinement.
To address whether EVs permeabilize the endosomal
membrane to escape from endosomes, a galectin-3-based
assay was used. For this purpose, HEK293T cells were
transduced to express monomeric azami green-tagged galectin-
3 (mAG-gal3) in their cytosol. mAG-gal3 identifies damaged
endosomes by binding to β-galactosides that are present at the
Figure 1. Experimental setup to elucidate the intracellular site of
EV-cargo release. EVs interacting with recipient cells can release
their cargo via: (i) direct fusion with the plasma membrane; (ii)
kiss and run fusion with the endoplasmic reticulum; (iii) fusion
with the endosome membrane; and (iv) endosomal rupture. (A) In
cells engineered to cytosolically express monomeric azami-green
galectin-3 fusion protein (mAG-gal3), mAG-gal3 punctae for-
mation only occurs in case of endosomal rupture (iv). (B) In cells
engineered to cytosolically express mCherry-tagged anti-GFP
fluobody, mCherry punctae formation only occurs in case of
fusion of GFP-CD63 EVs (i.e., membrane-bound GFP inside the
EV) with the plasma membrane (i) or endosome membrane (iii).
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luminal leaflet of endosomes, which results in the formation of
mAG-gal3 punctae (Figure 3A).40 To address whether mAG-
gal3 punctae (green) are formed upon incubation of
HEK293T cells with EVs, mAG-gal3 HEK293T cells were
incubated with red fluorescent CD63-RFP EVs (Figure S4).
A diffuse cytosolic green fluorescence without punctae was
observed in mAG-gal3 expressing HEK293T cells in the
presence of CD63-RFP EVs for 12 h, which was similar to in
untreated cells (Figure 3B). As a positive control, cells were
incubated with Lipofectamine-based lipoplexes, which are
known to disrupt endosomes.40 Indeed, multiple mAG-gal3
punctae were formed in cells treated with lipoplexes (Figure
3B, quantified in D). To exclude the possibility that mAG-gal3
punctae were present at earlier time points but disappeared
during the prolonged incubation time, mAG-gal3 cells were
incubated with RFP-tagged EVs for 2, 4, 8, and 12 h (Figure
S5), after which EV uptake and mAG-gal3 punctae were
quantified. Significant uptake of EVs by mAG-gal3 HEK293T
cells was seen after 2 h of incubation. A plateau in EV uptake
was reached after 4 h incubation, showing 66 ± 9 RFP-positive
spots per cell, indicating that EVs were efficiently internalized
by mAG-gal3 cells (Figure 3C, red line). However, a very
limited number of galectin punctae was observed at all of the
investigated time points (Figure 3C, green line), which was
similar to the number of punctae in untreated (control) cells
(Figure 3D). Moreover, no colocalization was observed
between CD63-RFP EVs and mAG-gal3 punctae at any of
the investigated time points. Live cell imaging of mAG-gal3
HEK293T cells incubated with CD63-RFP EVs for 4 h
confirmed the absence of mAG-gal3 punctae formation,
indicating that such events did not remain undetected because
of a transient nature of the mAG-gal3 punctae, nor that
Figure 2. Exogenously added EVs localize in membrane-bound compartments in HEK293T acceptor cells. (A) HEK293T cells incubated for
12 h with GFP-CD63 EVs show a punctate staining pattern in the cytosol (scale bars, 10 μm). (B) Correlative light (green) and EM
(greyscale) microscopy for ultrastructural analysis of the internalized EVs (GFP punctae) of the boxed area in (A) (scale bars, 5 μm). (C)
Underlying ultrastructures of areas 1−3 in (B) reveal vesicular structures. Additional snap shots available in Supplementary Figure 3B.
(Scale bars, 0.2 μm.) (D) Structures given in (C) are labeled with QDs (indicated by arrowhead) following anti-GFP immunolabeling,
confirming the presence of GFP-CD63 EVs within the vesicular structures (scale bars, 0.2 μm). All EM data sets at full resolution are
available via www.nanotomy.org.
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punctae were absent due to fixation-induced artifacts41 (Movie
S1 and still images in Figure S7). A five-times increase in the
EV concentration with the mAG-gal3 cells did not result in
mAG-gal3 punctae formation (Figure S6). Collectively, the
data show that internalized EVs do not permeabilize
endosomes in HEK293T cells.
Extracellular Vesicles Release Their Cargo from
Endosomes/Lysosomes. Next, we considered the involve-
ment of nondisruptive EV-endosome membrane fusion in the
unloading of EV cargo. To visualize EV cargo release into the
cell cytosol, we used a fluorescent membrane-bound cargo,
because a soluble cargo would rapidly dilute in the cytosol,
resulting in a fast loss of signal, precluding further investigation
by means of CLEM. Specifically, GFP-CD63 EVs with GFP
present at the N-terminal end of CD63, that is, inside the EVs,
were used (Figure S4A). First, the presence of GFP at the
inside of EVs was verified. To this end, GFP-CD63 EVs were
immuno-stained with anti-GFP antibody and secondary
antibody conjugated to gold without prior permeabilization.
WT EVs were used as a negative control, and EVs with GFP
fused to the extracellular loop of CD63 (outGFP-CD63 EVs)
were used as a positive control. OutGFP-CD63 EVs showed a
positive signal in immunostaining, whereas WT and GFP-
CD63 EVs showed no signal (Figure S4D). These data
confirm that GFP when fused at the N-terminal end of CD63
is not accessible to the anti-GFP antibody and thus present at
the inside of the EVs.
Then, HEK293T cells were engineered to express an anti-
GFP nanobody fused to mCherry (anti-GFP fluobody) in the
cytosol. Upon fusion of GFP-CD63 EVs with the endosomal
membrane, GFP that is present inside the EVs would become
exposed to the cytoplasm. Consequently, the cytosolic anti-
GFP fluobody would identify such a fusion event (Figure 4A).
Upon the incubation of fluobody-expressing HEK293T cells
with GFP-CD63 EVs, mCherry punctae were formed,
designating the cytosolic exposure of EV cargo (Figure 4B).
Fluobody punctae were present in nearly all cells (94% ± 4.4%;
Figure S8) after 12 h. In addition, maximum colocalization
(yellow) between EVs (green) and fluobody punctae (red) was
seen after 12 h of incubation, when 24% ± 1.2% of GFP spots
colocalized with mCherry punctae (Figure 4B, C). Impor-
tantly, mCherry punctae always colocalized with GFP spots,
validating the specificity of the anti-GFP fluobody. Moreover,
incubation of fluobody-expressing cells with WT EVs revealed
the absence of mCherry punctae, confirming the specificity of
mCherry puncta formation toward GFP-CD63 EVs (Figure
S9). Of note, the maximum EV/fluobody colocalization at t =
12 h does not mean that maximum cargo exposure occurs at
this time point. It more likely reflects persistence over time of
the structures from where release has taken place. Next, to
identify the underlying ultrastructure at the sites of
colocalization between GFP-CD63 EVs and fluobody punctae,
CLEM was performed. To maximize the chance of detecting
sites of EV-fluobody colocalization, mCherry-fluobody
HEK293T cells that were incubated with GFP-CD63 EVs
for 12 h were investigated. Ultrastructural analysis revealed the
presence of late endosomes/MVBs and lysosomes at the
intracellular sites of colocalization between EVs and fluobody
punctae (Figure 4D,E). This implies that EV cargo is released
from late endosomes and lysosomes and/or that EV cargo is
released from (early) endosomes that subsequently undergo
maturation. To confirm the identity of the endosomal
structures as revealed by CLEM investigation, fluobody-
expressing cells were incubated with GFP-CD63 EVs for 12
h and immunostained for LAMP1, a marker for both late
endosomes/MVBs and lysosomes. The extent of colocalization
between EV/fluobody spots and LAMP1 was 43 ± 13%
(Figure 4F). Altogether, the data demonstrate that a fraction of
internalized EVs undergoes fusion with endosomes and/or
lysosomes, resulting in EV cargo exposure to the cell cytosol.
Figure 3. EVs do not induce endosomal permeabilization. (A) Cartoon illustrating the galectin-3-based assay to detect endosomal
permeabilization. HEK293T cells are engineered to cytosolically express monomeric azami-green galectin-3 fusion protein (mAG-gal3).
Upon endosomal permeabilization, galactoside residues at the inner leaflet of the endosome are accessible to mAG-gal3, resulting in mAG-
gal3 accumulation in the endosome and puncta formation. (B) Fluorescence images of mAG-gal3 expressing HEK293T cells untreated
(control), treated with CD63-RFP EVs (EV) and transfected with Lipofectamine (Lipo) (t = 12 h). Red, EVs; green, mAG-gal3; blue,
nucleus (scale bars, 10 μm). (C) Quantification of CD63-RFP EV uptake (red line) and mAG-gal3 punctae formation (green line) in cells
over time (error bars represent SD, n = 3, ≥ 36 cells analyzed per time point). (D) Quantification of mAG-gal3 punctae upon 12 h treatment
of mAG-Gal3 HEK293T cells with EVs and Lipofectamine-based lipoplexes. mAG-gal3 punctae only appear in cells with lipoplex treatment
(n = 3; ≥ 45 cells analyzed per condition; **P < 0.01, ***P < 0.001, ns; not significant, ANOVA Tukey’s post hoc test).
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Neutral pH and Elevated Cholesterol in Endosomes
Block EV Content Release from Endosomes. Viral fusion
with endosomes has been shown to be pH and cholesterol
dependent.42 To address whether these factors also control EV
Figure 4. EV cargo release occurs from endosomes. (A) Cartoon illustrating the experimental design to identify EV cargo exposure to the cell
cytosol. When GFP-CD63 EVs in endosomes undergo fusion with the endosome membrane in anti-GFP fluobody (mCherry) HEK293T
cells, the anti-GFP fluobody can access and recognize the GFP at the EV interior, resulting in formation of mCherry punctae. (B)
Fluorescence images of anti-GFP fluobody (mCherry) HEK293T cells incubated with GFP-CD63 EVs for 4, 8, and 12 h. Yellow punctae
represent colocalization. Green, EV; red, fluobody (scale bars, 10 μm). (C) EV uptake (green line) and colocalization with fluobody punctae
(yellow line). Colocalization of GFP and mCherry indicate EV cargo exposure to the cell cytosol (error bars represent SD, n = 3, ≥ 36 cells
analyzed per time point). (D) Correlative light (red + green) and EM (greyscale) microscopy of anti-GFP fluobody (mCherry) cells
incubated with GFP-CD63 EVs for 12 h. Numbers 1−4 indicate areas of red and green (yellow) colocalization (scale bars, 2 μm). (E) The
underlying ultrastructure of intracellular sites of EV cargo exposure to the cell cytosol (areas 1−4 in D). Membrane-bound structures
containing numerous ILVs (1, 3, and 4) represent MVBs, while structures with electron-dense interior (2) represent lysosomes (scale bars,
0.2 μm). Complete data set at maximum resolution is available at www.nanotomy.org. (F) Immunostaining for the late endosome/lysosome
marker LAMP1 in anti-GFP fluobody cells incubated for 12 h with GFP-CD63 EVs. Green, EV; red, fluobody; 633, antibody staining color-
coded blue (scale bars, 10 μm).
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content release from endosomes, two metabolic inhibitors,
Bafilomycin A1 (BafA1) and U18666A, were used. BafA1 is a
V-ATPase inhibitor that prevents the acidification of endo-
somes during endosomal maturation.43 In the presence of
BafA1, fluobody punctae formation was almost completely
abolished in anti-GFP fluobody (mCherry)-expressing cells
that were treated with EVs (Figure 5A). The overlap between
GFP-CD63 EVs and fluobody punctae decreased 9-to-10-fold
as compared to untreated (control) cells (Figure 5B).
Importantly, treatment with BafA1 did not affect cell viability
and EV internalization (Figure S10A−B), while it effectively
prevented endosomal acidification (Figure S10C). Treatment
of cells with U18666A, an inhibitor of lysosomal cholesterol
export, has been shown to trigger cholesterol accumulation in
late endosomes and lysosomes.44,45 Incubation of anti-GFP
fluobody HEK293T cells with EVs in the presence of
U18666A resulted in a reduction in fluobody punctae
compared to incubation in the absence of U18666A (Figure
5A), while the colocalization between fluobody punctae and
GFP-CD63 EVs showed a 5-to-6-fold decrease (Figure 5B).
Treatment of HEK293T cells with U18666A resulted in
enlarged LAMP1-positive compartments and cholesterol
accumulation in endosomes (Figure S10D−E, respectively).
Collectively, the data indicate that EV-endosome membrane
fusion is inhibited by neutralization of endosomal pH and
cholesterol accumulation in endosomes, which prevents EV
content release from endosomes into the cytosol.
CONCLUSIONS
Extracellular vesicles (EVs), including exosomes, enable (long-
distance) cell−cell communication. Their potential use for
disease diagnosis and drug delivery is extensively investigated.
However, the mechanism of EV-mediated cargo transfer
between cells remains largely obscure. Different sites for EV
cargo release in acceptor cells have been proposed, including
(i) the plasma membrane,19 (ii) the endosome,22,25 and (iii)
the endoplasmic reticulum.21 In this study, an analytical
methodology was developed to visualize EV uptake and cargo
release in acceptor cells, in order to identify the intracellular
site for EV cargo release (Figure 1). Using correlative light and
electron microscopy (CLEM), a combination of fluorescence
microscopy and EM, we reveal the ultrastructural context of
cellular structures containing fluorescently labeled EVs (Figure
2). EV localization in endosomes and lysosomes confirmed
their uptake by endocytosis in line with hitherto reported
studies.21−24
Escape from endosomal confinement is necessary for EVs to
expose their cargo to the cytosol. Studying the fate of EV
cargoes has been challenging owing to the low quantities of
encapsulated cargo molecules.18,46 Despite the development of
tools to enhance EV loading efficiency, direct proof for cargo
release is lacking.23,24 Recently, EV cargo release from
endosomes was examined by the use of GFP-carrying EVs
labeled with a quenching concentration of R18.22 Dequenching
of the R18 probe at the level of late endosomes/MVBs
revealed membrane interaction between exosomes and late
endosomes/MVBs, indicative for cargo release at late endo-
somes/MVBs. However, dequenching of R18 shows dilution of
exosomal lipids and cannot distinguish endosomal rupture
from membrane fusion. Moreover, R18 dilution does not
demonstrate cargo exposure to the cytosol, and release of GFP
content from endosomes into the cytosol was not detected in
the study,22 possibly because release of soluble GFP cargo
remains undetected because of its rapid dilution in the cytosol.
In the present study, to increase the chance of detecting EV
cargo exposure to the cytosol of acceptor cells, a membrane-
bound EV cargo (i.e., GFP-CD63) was used. Formation of
mCherry punctae in mCherry-tagged anti-GFP nanobody-
expressing HEK293T cells upon their exposure to GFP-CD63
EVs revealed GFP exposure, that is, EV cargo delivery, to the
Figure 5. EV cargo release is blocked by treatment of acceptor cells with the V-ATPase inhibitor Bafilomycin A1 or U18666A, an inhibitor of
cholesterol export from late endosomes/lysosomes. (A) Anti-GFP fluobody (mCherry) expressing cells were incubated for 12 h with GFP-
CD63 EVs in the absence and presence of BafA1 or U18666A. Note that colocalization (yellow) between EVs (green) and fluobody punctae
(red) is largely absent in BafA1 and U18666A treated cells. Green, EV; red, fluobody; blue, nucleus (scale bars, 10 μm). (B) Quantification
of colocalization of GFP-CD63 EVs and fluobody punctae after 12 h incubation in the absence and presence of BafA1 or U18666A. Number
of GFP/mCherry double-positive spots in control cells is set at 100% (error bars indicate SD, n = 3, ≥ 24 cells analyzed per condition; *P <
0.05, **P < 0.001, two-tailed Student’s t-test).
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cytosol (Figure 4B,C). Examination of the underlying
ultrastructure at GFP/mCherry double-positive punctae
revealed late endosomes/MVBs and lysosomes (Figure
4D,E). This finding was corroborated by a positive
immunostaining for the late endosome/MVB and lysosome
marker LAMP1 at the double-positive punctae (Figure 4F). Of
note, mCherry punctae were never detected at the plasma
membrane, suggesting that EV fusion with the plasma
membrane (Figure 1B(i)) does not occur. However, taking
into consideration the possibility of rapid diffusion of lipids
and proteins at the plasma membrane, a failure to capture
fluobody punctae at the plasma membrane cannot be ruled
out. Therefore, with the presented data, we do not rule out the
possibility of direct fusion of EVs with the plasma membrane.
Endosomal permeabilization as the mechanism of EV cargo
release was excluded, because of the absence of mAG punctae
in EV-treated HEK293T acceptor cells expressing cytosolic
mAG-gal3 (Figure 3), specifying EV-endosome membrane
fusion as a mechanism behind EV cargo delivery to acceptor
cells. Of note, only a fraction of the EVs that were internalized
by cells exposed their cargo to the cytoplasm, varying from
10% after 2 h to 24.5% after 12 h of incubation. This shows
that functional delivery of EV cargo is limited. The design of
EVs with a higher propensity to fuse with (endosomal)
membranes will facilitate the advancement of improved EV-
based therapeutics. Such approaches may include insertion of
cell penetrating peptides (CPPs), (viral) fusogenic peptides/
proteins, and cationic lipids and are currently under
investigation.47−51 Moreover, surface functionalization of EVs
to alter their tissue tropism will enhance cell specificity and
prevent off-target effects. Combining the advantages of EVs,
that is, a biological delivery system, and synthetic delivery
systems provides opportunities to improve target specificity,
safety, and efficiency in drug delivery.51−55
EV entry by endocytosis and subsequent cargo release via
membrane fusion suggests that EVs exploit mechanisms akin to
certain viruses.19,56 These viruses exploit a low pH-induced
change in the tertiary structure of viral envelope proteins to
induce fusion with acidified endosomal compartments.42 A
reduction in EV cargo delivery to cytosol after inhibition of
endosomal acidification by Bafilomycin A1 showed that EVs
respond to low pH for undergoing membrane fusion with
endosomal membranes (Figure 5). Further investigation is
required to see if low pH can alter membrane characteristics of
the internalized EVs, rendering them susceptible for membrane
fusion. Importantly, at different stages of maturation, endo-
somes differ not only in their luminal pH but also in lipid and
protein composition.57,58 Anionic lipids in late endosomes
have been shown to act as cofactors for fusion of viruses with
the endosomal membrane.59 Likewise, the endosomal escape
of genetic cargo mediated by synthetic gene delivery vectors
was shown to occur from maturing endosomes,60 initiating
discussion on the involvement of a specific class of anionic
lipids in mediating endosomal escape.61,62 U18666A treatment
is well-known to trigger an accumulation of cholesterol and the
anionic lipid LBPA in maturing endosomes.63,64 In the present
study, a reduction in the number of fluobody punctae upon
treatment of anti-GFP fluobody expressing HEK293T cells
with GFP-CD63 EVs in the presence of U18666A (Figure 5)
revealed that EV cargo release was significantly inhibited in the
presence of the cholesterol transport inhibitor U18666A, even
though endosomal compartments in U18666A-treated cells
were acidic in nature, as indicated by the presence of
Lysotracker (Figure S10). This may suggest that the lipid
composition of the endosomal membrane plays a role in EV-
endosome membrane fusion.
Taken together, using a sophisticated approach that
combines CLEM, cytosolic expression of mAG-gal3 that
detects endosomal damage, and cytosolic expression of a
fluorescently tagged probe that recognizes EV cargo, we
provide experimental proof for the exposure of EV cargo to the
cytosol via fusion of EVs with endosomes/lysosomes. This
fusion event provides a possible target for treatment and/or
prevention of tumor progression, viral pathogenesis, and
neurodegenerative diseases where EVs have been implicated
as key mediators.2,4−6,65 Blocking EV cargo release by
manipulating the EV-endosome membrane fusion process
may assist in preventing or decelerating disease pathogenesis.
However, a safe disposal of the EVs, for example, through
lysosomal degradation, is required in addition to the
prevention of intracellular EV cargo release. For instance,
treatment of cells with U18666A, which prevents exosome-
endosome membrane fusion and consequently intracellular
cargo release, has been shown to stimulate exosome secretion
by cells.65 This would unwantedly increase the risk of
spreading the disease-causing entities. Indeed, inhibition of
exosome secretion by bacteria-infected macrophages was
shown to inhibit sepsis-induced inflammation and cardiac
dysfunction.66 Therefore, prevention of exosome secretion by
“diseased” cells and/or inhibition of exosome internalization
by surrounding cells may offer safer alternatives to inhibition of
EV cargo release in order to prevent EV-mediated spreading of
disease.
METHODS
Plasmids. N-Flag-Apex2-emGFP-CD63 (a gift from Nicole C.
Meisner-Kober)21 was amplified adding BsmBI site at both the ends
of the sequence. Next, the amplified segment was inserted into an
entry vector pENTR1A (a gift from Eric Campeau and Paul Kaufman;
Addgene, plasmid# 17398; http://n2t.net/addgene:17398; PRI-
D:Addgene_17398)67 by golden gate assembly method.68 The
plasmid obtained was then recombined with pLenti-CMV-Puro-
DEST (a gift from Eric Campeau and Paul Kaufman; Addgene,
plasmid# 17452; http://n2t.net/addgene:17452; PRID:Addg-
ene_17452)67 using a gateway LR clonase enzyme (ThermoFisher
Scientific, 11791100) to achieve the expression vector pLenti-CMV-
N-Flag-APEX2-emGFP-CD63-Puro-DEST. For GFP display at the
surface of EVs, emGFP was inserted at the second extracellular loop
of CD63 following a reported strategy, to generate pLenti-CMV-N-
CD63-emGFP-CD63-C-Puro-DEST.69 To generate the expression
vector pLenti-CMV-CD63-mRFP using the same cloning strategy,
CD63 was amplified from N-Flag-Apex2-emGFP-CD63, and mRFP
sequence was amplified from Lamp1-mRFP plasmid (a gift from
Walther Mothes; Addgene, plasmid# 1817; http://n2t.net/
addgene:1817; PRID:Addgene_1817).70 mAzami-Green (mAG)-
galectin 3 (Gal3) plasmid was a gift from Niels Geijsen (Addgene,
plasmid# 62734; http://n2t.net/addgene:62734; PRID:Addg-
ene_62734).71 The secretion signal peptide sequence in the
mCherry-APEX2-anti-GFP FLIPPER-body vector72 was removed
during PCR, and pLenti-CMV-mCherry-APEX2-anti-GFP FLIP-
PER-body-Puro-DEST was generated using aforementioned golden
gate and gateway cloning strategy. In this study, the APEX2 in the
FLIPPER-body was not used, and therefore the probe is called
fluobody in the text. Full sequences of used proteins are provided in
the Supporting Information.
Generation of EV Producer and Acceptor HEK293T Cell
Lines and Cell Culture. The EV producer cell lines (GFP-CD63
and CD63-RFP) and acceptor cell lines (mCherry anti-GFP fluobody
and galectin-3 Azami-Green) were created via lentiviral transduction
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followed by Puromycin (Sigma P8833) selection at 1 μg/mL.
HEK293T cells were cultured in DMEM (Gibco 41965-039)
supplemented with 10% fetal bovine serum (FBS, Bodinco, 5010)
and 1% penicillin-streptomycin sulfate (Gibco, 15140-122) at 37 °C
under 5% CO2. For LM imaging, acceptor cells were seeded on glass
coverslips coated (VWR, 631-0150) with poly L-lysine (Sigma, P-
2636). For CLEM imaging, acceptor cells were seeded on glass
bottom Petri dishes (Greiner, 627870). The Petri dishes were, before
cell seeding, sputter coated with 2 nm palladium/gold (Lei-
caSCD050) after which a pattern was made to enable to relocate
the ROI in EM as defined by LM.
Preparation of Exosome-Depleted Medium. DMEM contain-
ing 10% FBS was centrifuged at 110,000×g for 16 h at 4 °C to deplete
the fetal bovine serum-derived EVs. The resulting supernatant was
filter sterilized through a 0.2 μm filter (Millipore) and stored at 4 °C.
EV Isolation. EV-producer cells were seeded in T162 flasks
(Corning), and 15 mL exosome-depleted medium was added when
cells reached ∼40% confluence. 48 h later, medium was collected and
EVs were isolated by sequential centrifugation (Table S1). Please note
that the EV fraction obtained after ultracentrifugation at 100,000×g
represents small EVs. The final pellet was resuspended in 50 μL of
PBS, and protein concentration was measured with DC protein assay
kit (Bio-Rad, 5000114). EV concentrations are given as total EV
protein weight per volume (μg/mL). Of note, besides EVs, other
proteinaceous medium components may have become pelleted by
sequential centrifugation, which may have caused an overestimation of
the EV protein content.
SDS-PAGE and Western Blot. SDS-PAGE samples were
prepared using an established protocol.73 Briefly, after measuring
the protein content of EVs and cell lysates, 30 μg of protein per
sample was mixed with Laemmli loading buffer with SDS and protease
inhibitors (Roche, 11697498001). Samples were boiled for 5 min at
90 °C, loaded on a 10% SDS-PAGE gel, and subjected to
electrophoresis at 100 V for 2 h. After SDS-PAGE, proteins were
transferred to a polyvinylidene difluoride membrane (PVDF,
Millipore, IPFL00010) and blocked with Odyssey blocking buffer
(Li-COR, 927-40000) for 1 h at RT. Blots were incubated overnight
with primary antibodies (Table S2) in blocking buffer at 4 °C. Next,
blots were washed with 0.1% PBS-Tween 20 and subsequently
incubated in secondary antibody for 1 h at RT. They were washed
with 0.1% PBS-Tween 20 and imaged with an Odyssey Infrared
Imaging system (Li-COR).
Size, Polydispersity, and ζ-Potential of EVs. An EV suspension
with a concentration of 10 μg/mL in PBS was loaded into a folded
capillary cell (Malvern Instruments DTS1070) and measured on a
Zetasizer Nano ZS particle analyzer (Malvern Instruments) using a
633 nm laser. Dynamic light scattering measurements were performed
in triplicate. Size and polydispersity were calculated by the cumulant
analysis method using Zetasizer software version 7.10. The ζ-potential
was determined by measuring the electrophoretic mobility and
calculated using the Smoluchowski approximation.
mAG-gal3 Endosomal Permeabilization Assay. mAG-gal3
expressing HEK293T cells were seeded in 24-well plates on glass
coverslips at a density of 150 × 103 cells/mL (0.5 mL) and treated the
next day with 0.5 mL of 20 μg/mL CD63-RFP EVs for 2, 4, 8, or 12 h
in exosome-depleted medium. Lipoplex treatment was used as a
positive control. Lipoplexes composed of Lipofectamine 2000 and
pDNA were prepared according to the manufacturer’s instructions
and incubated with mAG-gal3 cells for 12 h in exosome-depleted
medium. Control cells were treated in exosome-depleted medium in
the absence of CD63-RFP EVs. The effect of a high(er) concentration
of CD63-RFP EVs on endosomal integrity in mAG-Gal3 expressing
cells was studied by using 0.5 mL of 100 μg/mL EVs, while keeping
the rest of the protocol unchanged. Cells were fixed (4% PFA) and
examined for mAG-gal3 punctae formation by fluorescence
microscopy (Leica DMI6000B fluorescence microscope (HCX PL
FLUOTAR 63×/N.A. 1.25 OIL).
anti-GFP Fluobody EV Cargo Release Assay. HEK293T cells
expressing mCherry anti-GFP fluobody were seeded in 24-well plates
on glass coverslips at a density of 150 × 103 cells/mL (0.5 mL). The
next day, cells were treated with 0.5 mL of 20 μg/mL GFP-CD63 EVs
for 2, 4, 8, or 12 h in an exosome-depleted medium. Control cells
were treated in exosome-depleted medium in the absence of GFP-
CD63 EVs. Cells were fixed, and mCherry fluobody punctae
formation was examined by fluorescence microscopy.
Pharmacological Inhibitor, Temperature, and Fluorescent
Tracer Treatments of HEK293T Cells. HEK293T cells expressing
mCherry anti-GFP fluobody were plated in 24-well plates on glass
coverslips at a density of 150 × 103 cells/mL (0.5 mL). The next day,
cells were treated with 0.1 μM Bafilomycin A1 (BafA1, Enzo
Lifesciences BML-CM110−0100) for 30 min in 0.5 mL of exosome-
depleted medium, followed by addition of 20 μg/mL (10 μg per well)
EVs in continued presence of the drug for 12 h. Cells were treated
with 1 μg/mL U18666A (Merck Millipore, 662015-10MG) for 4 h in
0.5 mL of exosome-depleted medium, followed by addition of 20 μg/
mL (0.5 mL) EVs in continued presence of the drug for 12 h.
LysoTracker Red DND-99 (Invitrogen, L7528) was added to cells in
the inhibitor experiments 1 h before fixation. TopFluor (Bodipy)-
cholesterol (Avanti lipids, 810255P) was added (10 μM) to the cells
for 1 h before addition of inhibitors. Cells were (pre)treated with 80
μM dynasore (Bioconnect, 2897/10) for 30 min in 0.5 mL of
exosome-depleted medium, followed by addition of 20 μg/mL (0.5
mL) EVs in continued presence of the drug for 2 h. To inhibit energy-
dependent passage across the plasma membrane, cells were incubated
at 4 °C for 30 min and then treated with 0.5 mL of 20 μg/mL GFP-
CD63 EVs in ice-cold EV-depleted medium for 1 h before fixation.
Control cells were treated similarly at 37 °C before fixation.
MTT Assay. The viability of HEK293T after exposure to
pharmacological inhibitors was evaluated by performing a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-
Aldrich #M2128) assay. Two ×104 (0.2 mL) HEK293T cells were
seeded in 96-well plates precoated with PLL. Cells were treated in
triplicate with 0.1 μM BafA1 and 1 μg/mL U18666A in exosome
depleted DMEM (final volume of 0.2 mL), for 21 h. Untreated cells in
exosome depleted DMEM were used as a negative control. During the
final 3 h of incubation, cells were exposed to 20 μL MTT solution (5
mg/mL in PBS). The medium was removed, and formazan crystals
were dissolved in 200 μL of DMSO. Upon complete solubilization of
the crystals, the optical density of each well was measured at a
wavelength of 520 nm using a microplate spectrophotometer
(μQuant, BIO-TEK Instruments inc).
Electron Microscopic Investigation of Isolated EVs. Isolated
EVs were fixed in 50 μL of 2% paraformaldehyde (PFA, Merck,
1.04005.1000) prepared in 0.1 M sodium cacodylate buffer pH 7.4
(Sigma, C0250-500g). Four μL of the EV solution was incubated on
Formvar-coated 150 meshed copper grids (Electron Microscopy
Sciences, 0150-Cu) for 25 min. The grids were rinsed with PBS for 1
min and subsequently incubated with 1% glutaraldehyde (GA,
Polysciences, 01909-100) in 0.1 M sodium cacodylate buffer pH 7.4
for 5 min followed by rinsing with Milli-Q 7 times. All steps were
performed at RT. For EV immunostaining, grids were incubated for 1
h with primary anti-GFP antibody, rinsed, and incubated for 1 h with
a secondary antibody conjugated to 10 nm gold. Next, grids were
incubated with 2% uranyl oxalate (pH7; SPI, 02624-AB) for 4 min on
ice, briefly rinsed, and incubated for 10 min in methyl cellulose-uranyl
acetate (pH 4) on ice. Images were generated by EM (FEI, CM100).
Fixation and Immunolabeling for LM. Cells were fixed for 30
min with 4% PFA in PBS and rinsed with PBS. Prior to
immunolabeling, cells were permeabilized (0.2% Tween-20 (Sigma,
P1379) in PBS) and treated with blocking solution (1 h; 3% BSA
(Sigma, A7906) in PBS). Cells were then incubated with primary
antibodies overnight at 4 °C (Table S2) in blocking solution followed
by rinsing with PBS. Next, cells were incubated with secondary
antibodies in blocking solution and subsequently rinsed with PBS.
DAPI (1 μg/mL in PBS; Sigma, D9542) was added for 20 min,
followed by rinsing with PBS and mounting of the coverslips using
Vectashield (Vector Laboratories, H-1000) onto microscope slides.
Images were generated using confocal microscopy (Leica SP8, HC PL
APO CS2 63×/N.A. 1.4). All steps were performed at RT unless
mentioned otherwise.
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Fixation and Imaging for CLEM. An equal volume of 2% PFA
and 0.2% GA in 0.1 M sodium cacodylate buffer (pH 7.4) was added
to the cells in medium and incubated for 10 min. Cells were then
incubated with fresh pure fixative (2% PFA and 0.2% GA) for 30 min
and rinsed twice with 0.1 M sodium cacodylate. All steps were
performed at RT. Fluorescent images were generated using confocal
microscopy (Zeiss LSM 780, Plan-Neofluar 63×/N.A. 1.3 Imm Corr
DIC M27 lens) before being processing for EM.
Embedding and EM. Epon EM embedding was performed as
described previously.74 The ROI identified by confocal microscopy
was traced using a stereo microscope by using the palladium/gold
marks. The selected areas were sawn out and trimmed prior to
ultrathin sectioning. Serial sections (100 nm) of entire cells were
collected on nickel one-hole grids (Electron Microscopy Sciences,
1000-Ni). For stabilization, the grids were pre-irradiated using a TEM
(FEI, CM100) at 80 kV. Subsequently, large-scale areas, with 2.5 nm
pixel size, were scanned using the STEM detector in a SEM (Zeiss
Supra55) at 28 kV.39,74 An overlay was made in Adobe Photoshop. All
data sets are available at www.nanotomy.org.
Post-Embedding Immunolabeling. Thin sections in Epon were
etched for 10 min in 1% periodic acid (Merck, 1.00524.0025) in Milli-
Q, followed by washes (3 × 2 min Milli-Q) and blocking with 1%
BSA in PBS for 30 min. Next, the sections were immunolabeled (anti-
GFP, Table S2) for 4 h, washed 2 × 5 min with PBS, and incubated
with a biotinylated secondary antibody (1 h). Samples were rinsed (3
× 5 min PBS) and incubated with Quantum dot 655 (QD655)-
labeled streptavidin for 1 h. Finally, sections were rinsed (3 × 5 min
PBS). Images were generated with 2.5 nm pixel size, using the STEM
detector in a SEM (Zeiss Supra55) at 28 kV.
LM Image Analysis. Representative images were selected and
cropped. The images were adjusted in Adobe Photoshop by adding a
layer to change the levels, which was implemented to all the images to
the same extent. Quantification analysis was performed on the
recorded z-stacks and analyzed using the software Icy.75 The
Colocalizer with binary and excel output plugin was used to
determine the number of EVs and fluobody spots and colocalization.
For colocalization studies in cells co-incubated with GFP-CD63
and CD63-RFP EVs, images were first adjusted in brightness/contrast
minimum and maximum before colocalization measurements were
applied. Brightness/contrast minimum and maximum were set at 2−
70 for GFP-CD63, and 1−35 for CD63-RFP.76 Next, Fiji plugin
colocalization threshold was used, without the use of a ROI, to obtain
the Pearson’s value for the whole image. For colocalization studies in
immunostained fluobody-expressing cells, fluobody (red channel)
adjustments were set at 11 (min) and 84 (max). Similarly, for LAMP1
(633 channel), brightness/contrast minimum-maximum was set at 0−
70. JACoP plugin was used to obtain the Mander’s coefficient.76
Values were calculated after setting a threshold to remove the
background to only include fluobody punctae (mCherry channel) or
LAMP1 (633 channel) spots.
Live Cell Imaging of mAG-gal3 HEK293T Cells. For live cell
imaging, cells were grown on glass bottomed 2-well plates (Lab-TEK
chambered coverglass, Thermo Fisher Scientific, Denmark). On the
day of the experiment, cells were placed in a DeltaVision Elite
microscope equipped with a temperature/CO2 controlled cabinet and
automated stage. HEK293T cells expressing mAG-gal3 were selected
before addition of CD63-RFP EVs. Experiments were carried out in
exosome-depleted medium. Image acquisition took place from 30 to
270 min after the addition of the CD63-RFP EVs to the cells using
softWoRx 6 acquisition and integrated deconvolution software (GE
Healthcare, Issaquah, WA). The UPLSAPO objective (100× oil, N.A.
1.4, WD 0.12 mm) and GFP/mCherry filter combination were used
for image acquisition. Images were further analyzed using Fiji.77
Statistical Analysis. Experiments were performed at n = 3. Data
are presented as mean ± SD. The significance of the difference
between two independent samples was determined using Student’s t
test. Groups were compared using one-way analysis of variance, with
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GFP-CD63 EVs isolated from HEK293T cells and GFP-
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CD63 EVs are taken up via endocytosis. Figure S3: EVs
localize in membrane-bound compartments in
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ing cells that show fluobody punctae after 2, 4, 8, and 12
h incubation with 20 μg/mL CD63-GFP EVs. Figure S9:
WT EVs do not induce fluobody punctae in anti-GFP
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of BafA1 and U18666A metabolic inhibitors on
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